ial blood gas analysis, alone or in combination, does not exclude PE.
Several studies have suggested that AaDO2 has a linear correlation to actual perfusion defect and is a sensitive indicator of resolved emboli. [4] [5] [6] In the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) study, a linear correlation existed between AaDO2 and PE severity, as determined by pulmonary artery mean pressure, and with the number of mismatched perfusion defects. 7 There is continued interest, however, in the possibility that different gradients of AaDO2 or other arterial blood gas analyses can be used to predict the prognosis of acute PE. The purpose of this study was to determine the efficacy of individual blood gas measurements in predicting morbidity and mortality of patients with acute PE.
Methods

Study Sample
This study retrospectively identified 114 consecutive patients hospitalized at Chang Gung Memorial Hospital, Taiwan, between May 2001 and July 2003 with acute PE diagnosed by spiral computed tomography (CT) or high probability ventilation -perfusion lung scan. During the first 24 h of admission, all enrolled patients underwent the first arterial blood gas analysis under room air. Patients with intermediate or low probability lung scans were excluded, as were patients with clinical suspicion of septic emboli or a history of chronic lung disease.
Acute PE was treated pharmacologically in all cases. During the acute phase, all patients received anticoagulant therapy with either unfractionated heparin dosed according to the activated partial thromboplastin time or weight-adjusted low-molecular heparin administered subcutaneously. Thrombolysis, which was required by 8 patients, consisted of a 2-h intravenous infusion of 100 mg recombinant tissue plasminogen activator without concomitant heparin. Oral warfarin with an international normalized ratio 2.0-3.0 was used for at least 6 months in all discharged patients. The hospital's Human Research Committee approved the study and all participants gave oral informed consent.
Clinical Features and Biochemical Data
Clinical characteristics of all enrolled patients were recorded: gender, age, duration of symptoms, underlying disease, and possible risk factors. Baseline biochemical data, such as blood urea nitrogen, serum creatinine, troponin I, D-dimer, arterial blood gas, and platelet count, were also recorded. Electrocardiography, chest X-ray and echocardiography findings were also reviewed.
The alveolar -arterial oxygen gradient was calculated as follows:
The arterial/alveolar oxygen tension ratio (a/APO2) was also calculated:
where PaCO2 is the partial pressure of carbon dioxide in arterial blood (mmHg), PaO2 is the partial pressure of oxygen in arterial blood (mmHg), and PAO2 is the partial pressure of oxygen in the alveoli. Measurements of arterial blood gases were obtained while the patient breathed room air. All measurements were obtained within 24 h prior to commencing anticoagulant therapy.
Clinical Endpoints
The primary endpoint was 30-day all-cause death and the secondary endpoint was a composite of 30-day death and in-hospital complications, including cardiopulmonary resuscitation, mechanical ventilation and vasopressors for systemic arterial hypotension. All enrolled patients were followed for >1 year.
Statistical Analysis
The Student's t-test was used to compare continuous variables, and the proportion test to compare proportional differences for categorical variables between different groups according to the primary and secondary endpoints. The chi-square test was also used for categorical variables.
Receiver operating characteristic (ROC) analyses were used to determine the high sensitivity of AaDO2 and a/APO2 cutoff value for predicting the primary and composite endpoints. The a/APO2-R was the reciprocal of a/APO2, which equals 1/(a/APO2). The reciprocal a/APO2 (a/APO2-R) was used to demonstrate the mirror curve of a/APO2 at the opposite side of the ROC analysis and was used to compared the predictive power of different ROC curves for AaDO2 and a/APO2.
Multivariate Cox regression analyses were used to estimate the cumulative probability of the primary and composite endpoints in patients with and without elevated AaDO2 and a/APO2. The Cox proportional hazard model was used to calculate the hazard ratios of clinical variables and AaDO2 and a/APO2 for predicting primary and composite endpoints. Multivariable analysis was then performed to identify predictors of 30-day death, using the proportional hazards model with calculation of 95% confidence intervals (CI). As 30-day endpoint data were complete for all study patients, no patient was censored.
Results
In total, 114 patients were enrolled and subject to analyses. Of them only 1 patient had an AaDO2 <20 mmHg. Follow-up assessment of patients was performed after at least 1 year. Table 1 shows the patients clinical characteristics according to the primary endpoint and Table 2 shows them according to the 30-day composite endpoint. There was a significant difference between the 2 groups for AaDO2 (p=0.012). A strong but insignificant trend existed for AaDO2 between the primary endpoint group and the 30day survival group (p=0.062). All-cause 30-day mortality was 17.5%. The 30-day composite event rate was 26.3%. Five clinical characteristics had a significant affect on the 30-day survival rate: presence of cancer, hypotension, thrombocytopenia, low PaCO2, and elevated troponin I. Other additive clinical characteristics affected the 30-day composite events: diabetes mellitus, AaDO2, a/APO2, renal insufficiency and right ventricular dilatation (RVD).
Statistical analysis demonstrated that thrombocytopenia and renal insufficiency were significantly different between the 30-day composite endpoint group and the 30-day composite event-free group (unpubl data). The incidence of thrombocytopenia was strongly and significantly different between both the 30-day mortality vs survival, and the 30day composite event vs event-free. The odds ratio for 30day mortality was 4.49 (95% CI 1.86-10.87) and for 30-day composite endpoint was 2.96 (95% CI 1.44-6.11).
This study used ROC curves to demonstrate differences in arterial blood gas variables (Fig 1) . The AaDO2 was best at predicting the 30-day composite endpoint. Reciprocal a/APO2 instead of a/APO2 was used to compare the prognostic effect of AaDO2 and a/APO2 (Fig 2) . The area under the ROC curve for a/APO2-R was slightly smaller than that for AaDO2 (0.650 vs 0.657). The ROC curves determined that AaDO2 was best at predicting short-term mortality. The optimal cut-off value for AaDO2 was 53 mmHg and using that to separate 30-day mortality and survival, the incidence of AaDO2 ≥53 mmHg also showed a significant difference between the 2 groups (Table 1 ). With 53 mmHg as the cut-off value for AaDO2, the positive predictive value for 30-day death was 25%, and the negative predictive value was as high as 92%. For the 30-day composite endpoint, the positive predictive value of AaDO2 was 35%, and the negative predictive value was 84%. A prognostic cut-off value of the a/APO2 ratio was 0.49. When a/APO2 was used instead of AaDO2, the positive predictive value for the primary endpoint was 26.5%, and negative predictive value was 89%. Moreover, for the secondary endpoint, the positive predictive value of a/APO2 was 39%, and negative predictive value was 83%. Figs 3 and 4 show the respective short-term and 1-year survival curves for mortality and the composite event. These curves also demonstrate a significant difference between both 30-day mortality vs survival, and the 30-day composite event vs event-free, based on the cut-off value for AaDO2 after adjusting for other significant interfering factors. For 30-day death, the hazard ratio of AaDO2 ≥53 mmHg was 3.55 (95% CI 1.19-10.62), and for the 30day composite event, the hazard ratio of AaDO2 ≥53 mmHg 
Discussion
Role of AaDO2 Analysis in Patients With PE
The AaDO2 is typically used as an index of gas exchange, and the factors influencing it are diffusion gradient, ventilation -perfusion imbalance and true shunt. The combination of AaDO2 and pulmonary artery pressure has been used for classifying PE. 8 Kunieda et al identified a positive correlation between AaDO2 and increased pulmonary vascular obstruction. 4 Although Paul et al observed that a normal AaDO2 did not exclude a diagnosis of acute PE, they also demonstrated a linear correlation between AaDO2, pulmonary artery pressure and the number of mismatched vascular perfusion defects. 6 The present study further assessed the utility of using AaDO2 to predict morbidity and mortality, and found that the optimal cut-off value for was 53 mmHg for 30-day mortality and a composite endpoint. We used different variables for arterial blood gas analysis (PaO2, PaCO2, AaDO2 and a/APO2) to evaluate the ability of each to predict short-term mortality and morbidity. The AaDO2 with a cut-off value of 53 mmHg was the best at predicting short-term mortality and morbidity. It had a high negative predictive rate and moderate positive predictive rate. Any patient with AaDO2 ≥53 mmHg has a moderate probability of morbidity and mortality. Mortality or morbidity was uncommon for any patient with AaDO2 <53 mmHg during the first 24 h of admission. Thus, AaDO2 can be used in combination with other parameters, such as hypotension, high troponin I, RVD, to improve the accuracy of prognostic evaluation. Additionally, Masami et al have documented that inverted T waves have prognostic significance in acute PE. 9 Therefore, the combination of initial AaDO2 and ECG indings may provide another approach for predicting clinical prognosis. Aggressive thrombolytic therapy should be considered for patients with an AaDO2 ≥53 mmHg.
Role of a/APO2 Analysis in Patients With PE
Gilbert et al 10 investigated the impact of fractional inspired oxygen concentration (FiO2) on the AaDO2 gradient and a/APO2 ratio in normal subjects. They demonstrated that a/APO2 provides a uniform guide to gas exchange function over the range of FiO2 used in clinical practice. Gilbert et al defined the lower limit of normal for the ratio as approximately 0.75, and indicated that the a/APO2 ratio is relatively unaffected by FiO2. Retrospective analysis of patient data in the present study showed that many patients underwent their first blood gas analysis under varying concentrations of oxygen support in the emergency room (ER). As the influence of inspirated oxygen on the AaDO2 has been documented, the study group was screened using the same oxygen concentration (room air) to avoid the influence of varying FiO2. In the real word, blood gas analysis could be checked under variable FiO2. When patients arrive at the ER with acute illness, oxygen will be administered by the first-line physician. Therefore, the present study also assessed the predictive power of a/APO2 and notably, it had similar but less predictive power than AaDO2 for the short-term composite endpoint. The a/APO2 was better than other blood gas analysis variables for predicting the shortterm composite endpoint. The ROC curves determined that the prognostic cut-off value of a/APO2 ratio was 0.49, which may be another method for adjusting the impact of different FiO2 in clinical practice. To examine this issue, future research will require an increased number of patients who were administered different oxygen ratios.
Conflicting Result for Hypoxemia
Although a normal PaO2 does not rule out PE, elevated PaO2 can assist in determining the hemodynamic severity in patients with documented PE. 6 In the Geneva score, hypoxemia is an important predictor of death. 11 Analysis of the results of the present study demonstrated that hypoxemia was not significantly different between short-term mortality vs survival groups and the composite endpoint vs composite event-free survival groups. This conflict was likely caused by different patient selection methods. We enrolled patients having a high probability lung scan or positive spiral CT, which is more severe disease than in other studies. In the landmark PIOPED study, only 41% of patients with PE had a high-probability lung scan; most (57%) had an intermediate-probability or low-probability scan. 7
Mechanism for Widening AaDO2 and Hypoxemia
Acute PE impairs the efficient transfer of oxygen and carbon dioxide across lungs. Decreased arterial PO2 (hypoxemia) and increased AaDO2 gradient are the most common gas exchange abnormalities. There are controversial statements about the mechanism of hypoxemia and increased AaDO2. D'Alonzo et al concluded that hypoxemia and increased AaDO2 was explained by large shunts. 12 Manier et al had another rationale for the mechanism of hypoxemia and increased AaDO2. They proposed that decreased mixed venous O2 plays a major role in patients with acute PE.
Hypoxemia and increased AaDO2 are promoted by a moderate increase in the fraction of blood flowing through low ventilation -perfusion units. Diffusion impairment plays only a minor role in the mechanism. 13 A low oxygen pressure in the venous blood may also contribute to arterial hypoxemia when PE causes right ventricular (RV) failure. Low cardiac output results in increased extraction of oxygen by the tissues, thereby reducing the partial oxygen pressure in venous blood below normal levels. Moreover, the importance of ventilation -perfusion inequality has also been addressed by other studies. 14, 15 When ventilation and perfusion are mismatched, blood flow from the obstructed pulmonary arteries is redirected to other gas exchange units, and shunting of venous blood into the systemic circulation can occur.
Significant Role of Thrombocytopenia in Acute PE
In the present study thrombocytopenia was associated with the severity of acute PE, as finding that has rarely been mentioned in the literature. Platelet reduction has been observed in patients with post-traumatic pulmonary microembolism. 16 In the present series there was a significant difference in the incidence of thrombocytopenia between the short-term morbidity and short-term composite endpoint groups. This phenomenon can be explained by increased platelet consumption in severe PE. Adverse consequences result from reduction of blood flow through the pulmonary vasculature because of mechanical obstruction, and local pulmonary vasoconstriction resulting from platelet-mediated release of humoral substances, including serotonin, adenosine diphosphate, prostaglandins, and thromboxane. [17] [18] [19] [20] Several physiological responses to platelet activation, such as pulmonary hypertension, bronchoconstriction, and RV failure, have been identified. 21 
Study Limitations
First, the limited sample size. A larger sample size would increase the difference in the AaDO2 between groups. Second, this uncontrolled retrospective study had a selection bias. According to the inclusion criteria, the patients had severe PE. In the landmark PIOPED study, most patients with PE (57%) had an intermediate-or low-probability scan, and 11-14% of the 280 patients had a normal AaDO2. In contrast, only 1 of 114 patients in the present study had a normal AaDO2.
Conclusion
Measurement of AaDO2 is a highly useful and simple measurement for predicting short-term mortality and composite events. It has high negative predictive value and moderate positive predictive value for 30-day death and 30-day composite events. The a/APO2 has a predictive ability that is similar to AaDO2. but further study is required to make a clear conclusion. Thrombocytopenia was also an indicator of poor prognosis for patients with acute PE and aggressive thrombolytic therapy should be considered for patients with an initial poor prognostic parameter of AaDO2 ≥53 mmHg.
